{
    "clinical_study": {
        "@rank": "43741", 
        "acronym": "CRADLE", 
        "arm_group": {
            "arm_group_label": "Pharmacokinetic samples", 
            "arm_group_type": "Experimental", 
            "description": "Pharmacokinetic (PK) samples will be taken from  breast milk of lactating mothers on an established dosing regimen of CZP on Day 0 of the Sampling Period, just prior to next scheduled dose of CZP, and on Days 2, 4, 6, 8, 10, 12, and 14, relative to CZP administration on Day 0. In addition, in mothers on a CZP Q4W dosing regimen, the concentration of CZP in breast milk will also be evaluated on or about Day 28 (ie, prior to and on the same day of the next scheduled administration of CZP).\nIncluded are mothers who decided to continue on, or to start treatment with, Certolizumab Pegol (CZP) for an approved indication with their treating physician prior to participation into this study. The mother is responsible for procuring her own supply of commercial CZP. The CZP dose and administration schedule will be as per the locally approved label."
        }, 
        "brief_summary": {
            "textblock": "The primary objectives of this study are to assess whether there is transfer of Certolizumab\n      Pegol (CZP) into breast milk of lactating mothers who are receiving an established dosing\n      regimen of CZP by evaluating the concentration of CZP in mature breast milk, and to\n      calculate the infant daily dose of maternal CZP."
        }, 
        "brief_title": "A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia\u00ae in Mature Breast Milk of Lactating Mothers", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Axial Spondyloarthritis (AxSpA)", 
            "Non-radiographic Evidence-AxSpA", 
            "Ankylosing Spondylitis", 
            "Crohn's Disease", 
            "Psoriatic Arthritis", 
            "Rheumatoid Arthritis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Psoriatic", 
                "Arthritis, Rheumatoid", 
                "Crohn Disease", 
                "Spondylitis", 
                "Spondylitis, Ankylosing", 
                "Spondylarthritis"
            ]
        }, 
        "detailed_description": {
            "textblock": "The study will only include women who are receiving treatment with Certolizumab Pegol (CZP)\n      for an approved indication in accordance with their treating physician, although this study\n      is non-interventional regarding treatment with CZP, it is considered interventional due to\n      the collection of breast milk from the lactating mothers."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  An IRB/IEC approved written Informed Consent form for participation of the maternal\n             subject and her infant (for collection of infant demographic and AE data) is signed\n             and dated by the subject. Where applicable, the written Informed Consent form with\n             respect to the infant is also signed and dated by the holder of parental rights as\n             designated by the maternal subject\n\n          -  Subject is considered reliable and capable of adhering to the protocol and visit\n             schedule according to the judgment of the Investigator\n\n          -  Subject is female and at least 18 years of age at the time of providing consent\n\n          -  Subject has delivered term infant(s) (at least 37 weeks gestation)\n\n          -  Subject is being treated with Certolizumab Pegol (CZP) per the current approved\n             prescribing information\n\n          -  The decision to treat with CZP or to breastfeed is made independently from and prior\n             to the subject consenting to participate in this study\n\n          -  Subject agrees to use only the emollient or nipple cream provided by the Sponsor for\n             use during the Sampling Period as described per protocol\n\n          -  Subject is at least 6 weeks postpartum\n\n          -  Subject is on an established dosing regimen of CZP (at least the third dose of CZP\n             since starting/restarting CZP)\n\n        Exclusion Criteria:\n\n          -  Subject is taking a prohibited medication or has taken a prohibited medication Note:\n             any subjects requiring antibiotics must be discussed with the Medical Monitor prior\n             to enrollment\n\n          -  Subject has history of chronic alcohol abuse or drug abuse in the last year\n\n          -  In subjects who intend to breastfeed, the infant has any abnormality noted on\n             physical examination that, in the opinion of the Investigator, may jeopardize or\n             compromise the subject's ability to participate in this study\n\n          -  Subject has any medical, obstetrical or psychiatric condition that, in the opinion of\n             the Investigator, can jeopardize or would compromise the subject's ability to\n             participate in this study or the outcome of the pregnancy (as applicable). Note:\n             subjects with mastitis infection should not have samples collected until the\n             infection is completely resolved\n\n          -  Subject has history of breast implants, breast augmentation, or breast reduction\n             surgery\n\n          -  Subject has previously participated in this study\n\n          -  Subject has participated in a study of an investigational medicinal product (IMP) (or\n             a medical device) within the previous 30 days or 5 half-lives (whichever is longer)\n             prior to Screening or is currently participating in another study of an IMP (or a\n             medical device) unless the study is UCB UP0017 [NCT02019602]  or a registry study\n\n          -  Subject has received treatment with any biological therapeutic agent, or other\n             anti-TNF agents with the exception of CZP, within 5 half-lives prior to obtaining the\n             first sample\n\n          -  Subject has a positive or indeterminate QuantiFERON\u00ae-TB GOLD In Tube test at\n             Screening. In case of indeterminate result, a retest is allowed if time permits; 2\n             results of indeterminate require exclusion of the subject. Tuberculosis (TB) test\n             results that have been obtained within the previous 60 days prior to Screening are\n             acceptable (QuantiFERON\u00ae-TB GOLD or purified protein derivative [PPD] test)\n\n          -  Subject has known TB infection, at high risk of acquiring TB infection or latent TB\n             infection"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "16", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 30, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02154425", 
            "org_study_id": "UP0016", 
            "secondary_id": "2013-004126-28"
        }, 
        "intervention": [
            {
                "arm_group_label": "Pharmacokinetic samples", 
                "description": "Pharmacokinetic (PK) samples will be taken from  breast milk of lactating mothers on an established dosing regimen of CZP on Day 0 of the Sampling Period, just prior to next scheduled dose of CZP, and on Days 2, 4, 6, 8, 10, 12, and 14, relative to CZP administration on Day 0. In addition, in mothers on a CZP Q4W dosing regimen, the concentration of CZP in breast milk will also be evaluated on or about Day 28 (ie, prior to and on the same day of the next scheduled administration of CZP).", 
                "intervention_name": "Breast milk sampling", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "Pharmacokinetic samples", 
                "description": "Mothers who decided to continue on, or to start treatment with, Certolizumab Pegol (CZP) for an approved indication with their treating physician prior to participation into this study. The mother is responsible for procuring her own supply of commercial CZP. The CZP dose and administration schedule will be as per the locally approved label.", 
                "intervention_name": "Certolizumab Pegol", 
                "intervention_type": "Biological", 
                "other_name": "Cimzia\u00ae"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Immunoglobulin Fab Fragments"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Cimzia\u00ae", 
            "CZP", 
            "Breastfeeding", 
            "Autoimmune diseases and pregnancy"
        ], 
        "lastchanged_date": "June 3, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Chapel Hill", 
                    "country": "United States", 
                    "state": "North Carolina"
                }, 
                "name": "1"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Multicenter, Postmarketing Study to Evaluate the Concentration of Certolizumab Pegol in the Breast Milk of Mothers Receiving Treatment With Cimzia\u00ae (Certolizumab Pegol) Phase 1B (Clinical Pharmacology)", 
        "overall_contact": {
            "last_name": "UCB Clinical Trial Call Center", 
            "phone": "+1 877 822 9493"
        }, 
        "overall_official": {
            "affiliation": "+1 877 822 9493 (UCB)", 
            "last_name": "UCB Clinical Trial Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "France: Conseil National de l'Ordre des M\u00e9decins", 
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "France: Committee for the Protection of Personnes", 
                "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)", 
                "Netherlands: Medical Ethics Review Committee (METC)", 
                "Switzerland: Ethikkommission", 
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Mature breast milk samples will be collected predose on Day 0 of the Sampling Period (CZP dosing day) for all subjects.", 
                "measure": "The concentration of Certolizumab Pegol (CZP) in breast milk on Day 0", 
                "safety_issue": "No", 
                "time_frame": "Day 0"
            }, 
            {
                "description": "Mature breast milk samples will be collected on Day 2 of the Sampling Period for all subjects.", 
                "measure": "The concentration of Certolizumab Pegol (CZP) in breast milk on Day 2", 
                "safety_issue": "No", 
                "time_frame": "Day 2"
            }, 
            {
                "description": "Mature breast milk samples will be collected on Day 4 of the Sampling Period for all subjects.", 
                "measure": "The concentration of Certolizumab Pegol (CZP) in breast milk on Day 4", 
                "safety_issue": "No", 
                "time_frame": "Day 4"
            }, 
            {
                "description": "Mature breast milk samples will be collected on Day 6 of the Sampling Period for all subjects.", 
                "measure": "The concentration of Certolizumab Pegol (CZP) in breast milk on Day 6", 
                "safety_issue": "No", 
                "time_frame": "Day 6"
            }, 
            {
                "description": "Mature breast milk samples will be collected on Day 8 of the Sampling Period for all subjects.", 
                "measure": "The concentration of Certolizumab Pegol (CZP) in breast milk on Day 8", 
                "safety_issue": "No", 
                "time_frame": "Day 8"
            }, 
            {
                "description": "Mature breast milk samples will be collected on Day 10 of the Sampling Period for all subjects.", 
                "measure": "The concentration of Certolizumab Pegol (CZP) in breast milk on Day 10", 
                "safety_issue": "No", 
                "time_frame": "Day 10"
            }, 
            {
                "description": "Mature breast milk samples will be collected on Day 12 of the Sampling Period for all subjects.", 
                "measure": "The concentration of Certolizumab Pegol (CZP) in breast milk on Day 12", 
                "safety_issue": "No", 
                "time_frame": "Day 12"
            }, 
            {
                "description": "Mature breast milk samples will be collected (predose, as applicable for subjects receiving CZP 200 mg Q2W) on Day 14 of the Sampling Period for all subjects.", 
                "measure": "The concentration of Certolizumab Pegol (CZP) in breast milk on Day 14", 
                "safety_issue": "No", 
                "time_frame": "Day 14"
            }, 
            {
                "description": "In subjects receiving CZP 400 mg Q4W, a mature breast milk sample will be collected on or about Day 28, prior to the next scheduled administration of CZP.", 
                "measure": "The concentration of Certolizumab Pegol (CZP) in breast milk on Day 28", 
                "safety_issue": "No", 
                "time_frame": "Day 28"
            }, 
            {
                "description": "Mature breast milk samples will be collected predose on Day 0 of the Sampling Period for all subjects.", 
                "measure": "The calculated infant daily dose of Certolizumab Pegol (CZP) in breast milk on Day 0", 
                "safety_issue": "No", 
                "time_frame": "Day 0"
            }, 
            {
                "description": "Mature breast milk samples will be collected on Day 2 of the Sampling Period for all subjects.", 
                "measure": "The calculated infant daily dose of Certolizumab Pegol (CZP) in breast milk on Day 2", 
                "safety_issue": "No", 
                "time_frame": "Day 2"
            }, 
            {
                "description": "Mature breast milk samples will be collected on Day 4 of the Sampling Period for all subjects.", 
                "measure": "The calculated infant daily dose of Certolizumab Pegol (CZP) in breast milk on Day 4", 
                "safety_issue": "No", 
                "time_frame": "Day 4"
            }, 
            {
                "description": "Mature breast milk samples will be collected on Day 6 of the Sampling Period for all subjects.", 
                "measure": "The calculated infant daily dose of Certolizumab Pegol (CZP) in breast milk on Day 6", 
                "safety_issue": "No", 
                "time_frame": "Day 6"
            }, 
            {
                "description": "Mature breast milk samples will be collected on Day 8 of the Sampling Period for all subjects.", 
                "measure": "The calculated infant daily dose of Certolizumab Pegol (CZP) in breast milk on Day 8", 
                "safety_issue": "No", 
                "time_frame": "Day 8"
            }, 
            {
                "description": "Mature breast milk samples will be collected on Day 10 of the Sampling Period for all subjects.", 
                "measure": "The calculated infant daily dose of Certolizumab Pegol (CZP) in breast milk on Day 10", 
                "safety_issue": "No", 
                "time_frame": "Day 10"
            }, 
            {
                "description": "Mature breast milk samples will be collected on Day 12 of the Sampling Period for all subjects.", 
                "measure": "The calculated infant daily dose of Certolizumab Pegol (CZP) in breast milk on Day 12", 
                "safety_issue": "No", 
                "time_frame": "Day 12"
            }, 
            {
                "description": "Mature breast milk samples will be collected (predose, as applicable for subjects receiving CZP 200 mg Q2W) on Day 14 of the Sampling Period for all subjects.", 
                "measure": "The calculated infant daily dose of Certolizumab Pegol (CZP) in breast milk on Day 14", 
                "safety_issue": "No", 
                "time_frame": "Day 14"
            }, 
            {
                "description": "In subjects receiving CZP 400 mg Q4W, a mature breast milk sample will be collected on or about Day 28, prior to the next scheduled administration of CZP.", 
                "measure": "The calculated infant daily dose of Certolizumab Pegol (CZP) in breast milk on Day 28", 
                "safety_issue": "No", 
                "time_frame": "Day 28"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02154425"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "UCB, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "UCB BIOSCIENCES, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}